. Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. Neurology. 2009 Sep 22;73(12):935-40. PubMed.

AlzBiomarker Database

Meta-Analysis

Curated Study Data

Biomarker
(Source)
Cohort
(N)
Measurement
Mean ± SD
Method;
Assay Name;
Manufacturer
Diagnostic
Criteria
Aβ42
(CSF)
AD
(31)
402 ± 113
pg/mL
ELISA;
Innotest;
Innogenetics
McKhann et al., 1984
Aβ42
(CSF)
CTRL-
Other Controls
(19)
688 ± 251
pg/mL
ELISA;
Innotest;
Innogenetics
tau-p181
(CSF)
AD
(31)
92 ± 38
pg/mL
ELISA;
Innotest;
Innogenetics
McKhann et al., 1984
tau-p181
(CSF)
CTRL-
Other Controls
(19)
63 ± 35
pg/mL
ELISA;
Innotest;
Innogenetics
tau-total
(CSF)
AD
(31)
811 ± 486
pg/mL
ELISA;
Innotest;
Innogenetics
McKhann et al., 1984
tau-total
(CSF)
CTRL-
Other Controls
(19)
432 ± 394
pg/mL
ELISA;
Innotest;
Innogenetics

Recommends

Please login to recommend the paper.

Comments

Make a Comment

Comments on this Paper

  1. This is an interesting paper that adds additional information about the value of multiple biomarkers as predictors of future decline in older persons. Specifically, CSF pTau predicted subsequent hippocampal atrophy independent of baseline atrophy and cognitive impairment. These data add to our knowledge about the utility of individual and combinations of biomarkers for predicting subsequent neurodegeneration.

Make a Comment

To make a comment you must login or register.